Skip to content
Bored Studies
RecruitingPhase 3

An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD

Transcend Therapeutics · NCT07836647

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 3
Target enrollment
300
US sites recruiting
2
Study start
September 2026
Record last updated
September 23, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This study is evaluating the safety and efficacy of TSND-201 in adults with PTSD. Eligible participants will enter a 4-week Treatment Period where they will be randomized 1:1:1 to receive one of two doses of TSND-201 or placebo, once per week. Following the Treatment Period, participants will enter an 8-week Follow-up Period.

Being studied: TSND-201; Placebo

Conditions: Post Traumatic Stress Disorder

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Meets DSM-5 criteria for current PTSD diagnosis, with a symptom duration of at least 6 months.
  • Tried at least one pharmacological treatment for PTSD or trauma-focused psychotherapy.
  • Proficient in communication (verbal and reading) to complete interviews and written questionnaires.
  • Free from any other clinically significant illness or disease.

Exclusion Criteria

  • Primary diagnosis of any other DSM-5 disorder.
  • Body mass index (BMI) \<18kg/m2 or ≥40 kg/m2.
  • Unable to refrain from nicotine use for at least 8 hours.
  • Use of prohibited concomitant medications or therapies.
  • Current or previous history of clinically significant cardiovascular (including current uncontrolled hypertension) / cerebrovascular conditions.

Recruiting US locations

  • Mountain View Clinical Research

    Denver, CO 80209

    Site contact: Brian Johnson · 720-941-9363 · brian@mtnresearch.com

  • Bradenton Research Center

    Bradenton, FL 34205

    Site contact: Gloria Carlbert, Site Director · 941-708-0005 · gloriacarlbert@bradentonresearch.com

Study contacts (from the official record)

  • Study Director · 650-769-6472 · amanda@transcendtherapeutics.com
All mental health studies in Colorado →
An Evaluation of the Safety and Efficacy of TSND-201 for the… (NCT07836647) | Bored Studies